-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) PT Lowered to $24 at H.C. Wainwright
-
-
-
-
-
-
-
US FDA Actively Reevaluating Whether to Proceed with the Advisory Committee Meeting for Capricor Cell Therapy - Reuters
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR); 'Calm Down People'
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
-
15,770 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

